MedTrace Logo

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

NCT05352750 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-02-03

No results posted yet for this study

Summary

This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor
  • Soft Tissue Sarcoma Adult

Interventions

BIOLOGICAL

SON-1010

SON-1010 is a recombinant, single-chain, unmodified human rIL-12 joined by a flexible linker to the fully human albumin binding (FHAB) domain that "hitch-hikes" on serum albumin for transport to the tumor microenvironment.

Sponsors & Collaborators

  • Sonnet BioTherapeutics

    lead INDUSTRY

Principal Investigators

  • Richard Kenney, MD · Sonnet BioTherapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-20
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05352750 on ClinicalTrials.gov